Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.

Cancer - 15 Feb 2012

Quintás-Cardama Alfonso, Verstovsek Srdan

Abstract excerpt

The myeloproliferative neoplasms (MPNs) essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are malignancies that frequently harbor the recurrent somatic point mutation JAK2(V617F). The discovery of this mutation has fueled the development of Janus kinase 2 (JAK2) inhibitors. Available results have indicated that JAK2 inhibitors are particularly effective at reducing spleen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemorrhage
Share to Myeloproliferative Disorders
Share to Organ Size

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Splenomegaly

Share to Thrombocythemia, Essential

Share to Thrombosis

Source

Identifiers

PMID: 21766300
DOI: 10.1002/cncr.26359

Genes

JAK2
JAK1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.PMID 21766300Read ↗

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 inhibitors: what's the true therapeutic potential?Semantic proximity Read ↗

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Semantic proximity Read ↗

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Therapeutic potential of JAK2 inhibitorsSemantic proximity Read ↗

Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

Emerging treatments for classical myeloproliferative neoplasms.Semantic proximity Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

Primary Myelofibrosis: Update on Definition, Pathogenesis, and TreatmentSemantic proximity Read ↗

'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.Semantic proximity Read ↗

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.Semantic proximity Read ↗

The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.